Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Ltd ( (HK:9688) ) just unveiled an announcement.
Zai Lab Limited has disclosed the current composition of its board of directors, led by Chairperson and Chief Executive Officer Dr. Samantha Du and supported by a group of independent directors. The announcement details the directors’ specific roles across five board committees, including audit, compensation, nominating and corporate governance, research and development, and commercial, clarifying leadership and oversight responsibilities.
The update highlights which directors chair and sit on each committee, with figures such as Scott W. Morrison leading the audit committee and Michel Vounatsos chairing the commercial committee. This structure underscores Zai Lab’s emphasis on corporate governance, scientific oversight, and commercial strategy, providing investors and other stakeholders with transparency into how board-level responsibilities are allocated.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong. The company focuses on developing and commercializing innovative medicines, supported by a board structure that includes independent directors and specialized committees overseeing key governance areas.
Average Trading Volume: 10,427,330
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.07B
See more data about 9688 stock on TipRanks’ Stock Analysis page.